Chief Executive Officer & Executive Director, AstraZeneca PLC
Most recently reported pay: $8.3M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
Oct 26, 2026https://www.globenewswire.com/news-release/2026/10/26/3387851/0/en/hutchmed-highlights-sanovo-phase-iii-data-for-orpathys-plus-tagrisso-in-first-line-egfr-mutated-lung-cancer-presented-at-esmo-congress-2026.htmlsentiment +0.80
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
Oct 26, 2026https://www.globenewswire.com/news-release/2026/10/26/3387782/0/en/hutchmed-highlights-saffron-global-phase-iii-data-presented-at-esmo-congress-2026-and-simultaneously-published-in-the-new-england-journal-of-medicine.htmlsentiment +0.80
Biotech stocks are surging. How investors can play the new drug innovation boom
Oct 24, 2026https://www.cnbc.com/2026/10/24/biotech-stocks-drug-innovation-rally.htmlsentiment +0.70
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Oct 24, 2026https://www.prnewswire.com/news-releases/imdelltra-in-combination-with-imfinzi-reduced-risk-of-death-by-an-unprecedented-58-in-first-line-extensive-stage-small-cell-lung-cancer-302918652.htmlsentiment +0.80
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript
Oct 12, 2026https://seekingalpha.com/article/4953592-astrazeneca-plc-azn-presents-at-american-society-for-bone-and-mineral-research-asbmr-2026sentiment +0.00
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Oct 10, 2026https://www.fool.com/investing/2026/10/10/alnylam-vs-ionis-heres-the-better-bad-news-buy/sentiment -0.30
